181 related articles for article (PubMed ID: 34750815)
1. "Real-world" eligibility for aducanumab depends on clinical setting and patients' journey.
Padovani A; Caratozzolo S; Rozzini L; Pilotto A; Benussi A; Tedeschi G
J Am Geriatr Soc; 2022 Feb; 70(2):626-628. PubMed ID: 34750815
[TBL] [Abstract][Full Text] [Related]
2. Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.
Anderson TS; Ayanian JZ; Souza J; Landon BE
JAMA; 2021 Oct; 326(16):1627-1629. PubMed ID: 34499725
[TBL] [Abstract][Full Text] [Related]
3. Making the Case for the Accelerated Withdrawal of Aducanumab.
Whitehouse PJ; Saini V
J Alzheimers Dis; 2022; 87(3):999-1001. PubMed ID: 35491796
[TBL] [Abstract][Full Text] [Related]
4. Aducanumab and the Business of Alzheimer Disease-Some Choice.
Karlawish J
JAMA Neurol; 2021 Nov; 78(11):1303-1304. PubMed ID: 34410302
[No Abstract] [Full Text] [Related]
5. The Problem of Aducanumab for the Treatment of Alzheimer Disease.
Alexander GC; Karlawish J
Ann Intern Med; 2021 Sep; 174(9):1303-1304. PubMed ID: 34138642
[No Abstract] [Full Text] [Related]
6. A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab.
Emanuel EJ
JAMA; 2021 Oct; 326(14):1367-1368. PubMed ID: 34554184
[No Abstract] [Full Text] [Related]
7. What the Aducanumab Approval Reveals About Alzheimer Disease Research.
Manly JJ; Glymour MM
JAMA Neurol; 2021 Nov; 78(11):1305-1306. PubMed ID: 34605885
[No Abstract] [Full Text] [Related]
8. Editorial: How Will Aducanumab Approval Impact AD Research?
Weiner MW; Aisen PS; Beckett LA; Green RC; Jagust W; Morris JC; Okonkwo O; Perrin RJ; Petersen RC; Rivera Mindt M; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ
J Prev Alzheimers Dis; 2021; 8(4):391-392. PubMed ID: 34585209
[No Abstract] [Full Text] [Related]
9. [Aducanumab approval for Alzheimer's disease in the USA: the surrender of science].
Dal-RĂ© R
Rev Neurol; 2021 Oct; 73(8):296-297. PubMed ID: 34617583
[TBL] [Abstract][Full Text] [Related]
10. How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond.
Lythgoe MP; Prasad V
Eur J Cancer; 2021 Nov; 157():68-70. PubMed ID: 34487987
[No Abstract] [Full Text] [Related]
11. "Real world" eligibility for aducanumab.
Canevelli M; Rossi PD; Astrone P; Consorti E; Vanacore N; Cesari M
J Am Geriatr Soc; 2021 Oct; 69(10):2995-2998. PubMed ID: 34331706
[No Abstract] [Full Text] [Related]
12. US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
Planche V; Villain N
JAMA Neurol; 2021 Nov; 78(11):1307-1308. PubMed ID: 34515750
[No Abstract] [Full Text] [Related]
13. Of education and public policy: Aducanumab.
Lundebjerg NE; Hollmann PA; Supiano MA
J Am Geriatr Soc; 2022 Jan; 70(1):81-84. PubMed ID: 34674219
[No Abstract] [Full Text] [Related]
14. Revisiting FDA Approval of Aducanumab.
Alexander GC; Knopman DS; Emerson SS; Ovbiagele B; Kryscio RJ; Perlmutter JS; Kesselheim AS
N Engl J Med; 2021 Aug; 385(9):769-771. PubMed ID: 34320282
[No Abstract] [Full Text] [Related]
15. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
Schulman KA; Greicius MD; Richman B
JAMA; 2021 Aug; 326(5):383-384. PubMed ID: 34279572
[No Abstract] [Full Text] [Related]
16. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
Alexander GC; Emerson S; Kesselheim AS
JAMA; 2021 May; 325(17):1717-1718. PubMed ID: 33783469
[No Abstract] [Full Text] [Related]
17. Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease.
Zissimopoulos J; Jacobson M; Chen Y; Borson S
JAMA Netw Open; 2022 Feb; 5(2):e2148355. PubMed ID: 35157058
[TBL] [Abstract][Full Text] [Related]
18. Accelerated Approval of Aducanumab: Where Do We Stand Now?
Barenholtz Levy H
Ann Pharmacother; 2022 Jun; 56(6):736-739. PubMed ID: 34595939
[TBL] [Abstract][Full Text] [Related]
19. Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies.
Yuksel JM; Noviasky J; Britton S
Sr Care Pharm; 2022 Aug; 37(8):329-334. PubMed ID: 35879846
[No Abstract] [Full Text] [Related]
20. Update: FDA approval of Biogen's aducanumab.
Hollmann P
Geriatr Nurs; 2022; 43():318-319. PubMed ID: 34996638
[No Abstract] [Full Text] [Related]
[Next] [New Search]